The Latest Breaking News from BIIB

: Major stock indices appear heading for weekly gains with the Fed’s first interest rate hike digested easily by investors. However, the market is expected to remain under pressure in the near term. So, because wide-moat companies generally do well in these market conditions, we think cheap wide-moat stocks Bristol-Myers…

Biogen Inc (NASDAQ:BIIB) has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease. The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta…

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have 

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Biogen Inc (NASDAQ: BIIB) has 

Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion.